Allakos announces publication of AK006 mechanism of action manuscript

Allakos announced the publication of "Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells," in Communications Biology. The publication describes the generation of Siglec-6 agonist monoclonal antibodies optimized for mast cell inhibition and their ability to suppress mast cell activity in pre-clinical models. Publication Details: The paper describes the identification of an epitope within the extracellular domain of Siglec-6 that allows for prolonged residence time on the mast cell surface. Key findings of the publication include: Identification of a Siglec-6 antibody that confers optimal mast cell inhibitory activity and ADCP function; dministration of this Siglec-6 antibody prevents systemic anaphylaxis in humanized mice with a single dose and reduces mast cell numbers with multiple doses; Engagement of Siglec-6 with an agonistic antibody induces formation of immunoregulatory synapses that recruit inhibitory signaling molecules that are required for potent mast cell inhibition. Allakos is currently completing IND-enabling studies and expects to begin in-human studies in the first half of 2023 in healthy volunteers and subsequently in patients with mast cell driven diseases.